Royal Philips announces that the U.S. FDA has issued an Emergency Use Authorization (EUA) for Philips’ IntelliVue Patient Monitors MX750/MX850 and its IntelliVue Active Displays AD75/AD85, for use in the U.S. during the COVID-19 health emergency. These patient monitoring solutions support infection-control protocols and remotely provide critical patient information for caregivers, capabilities that are much needed when caring for hospitalized COVID-19 patients.
Philips’ IntelliVue Patient Monitors MX750/MX850 and IntelliVue Active Displays AD75/AD85 received the CE mark in 2019 and are already being used in hospitals across Europe. The EUA allows Philips to start delivering the new remote patient monitoring solution to hospitals in the U.S., and the company is committed to submitting a 510(k) to FDA for this acute care solution in the course of 2020.
“As the world continues to battle against COVID-19, we’re committed to ramping up production of all critical solutions that can help in this time of crisis,” says Peter Ziese, general manager, monitoring and analytics at Philips. “This FDA EUA for our MX750 and MX850 monitors and IntelliVue AD75 and AD85 Active Displays allows us to do that for these remote patient monitoring solutions, which are of vital need in the ICU.”
The IntelliVue Patient Monitors MX750/MX850 and IntelliVue Active Displays AD75/AD85 offer advanced functionality and clinical decision support capabilities such as Philips’ IntelliVue Horizon Trends information view, which shows deviations in vital signs (for example, CO2 and heart rate) to contextualize a patient’s condition, while also supporting infection-control protocols and access to key information both remotely and at the bedside.